Center for Integrated Protein Science Munich (CIPSM), Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377, Munich, Germany,
Adv Exp Med Biol. 2014;801:733-9. doi: 10.1007/978-1-4614-3209-8_92.
Retinitis pigmentosa (RP) is a severe retinal disease characterized by a progressive degeneration of rod photoreceptors and a secondary loss of cone function. Here, we used CNGB1-deficient (CNGB1(-/-)) mice, a mouse model for autosomal recessive RP, to evaluate the efficacy of adeno-associated virus (AAV) vector-mediated gene therapy for the treatment of RP. The treatment restored normal expression of rod CNG channels and rod-driven light responses in the CNGB1(-/-) retina. This led to a substantial delay of retinal degeneration and long-term preservation of retinal morphology. Finally, treated CNGB1(-/-) mice performed significantly better than untreated mice in a rod-dependent vision-guided behavior test. In summary, this study holds promise for the treatment of rod channelopathy-associated retinitis pigmentosa by AAV-mediated gene replacement.
色素性视网膜炎(RP)是一种严重的视网膜疾病,其特征是视杆光感受器进行性退化和继发的视锥细胞功能丧失。在这里,我们使用 CNGB1 缺陷(CNGB1(-/-))小鼠,一种常染色体隐性遗传 RP 的小鼠模型,来评估腺相关病毒(AAV)载体介导的基因治疗治疗 RP 的疗效。该治疗方法恢复了 CNGB1(-/-)视网膜中视杆 CNG 通道和视杆驱动的光反应的正常表达。这导致视网膜变性的显著延迟和视网膜形态的长期保存。最后,在视杆依赖性视觉引导行为测试中,经过治疗的 CNGB1(-/-) 小鼠的表现明显优于未经治疗的小鼠。总之,这项研究为 AAV 介导的基因替代治疗与视杆通道病相关的色素性视网膜炎提供了希望。